PEG Ratio

The PEG ratio (price-to-earnings divided by expected earnings growth) of 4.82x means AstraZeneca’s stock price is relatively expensive compared to its projected earnings growth.

This is far above the sector median of 0.77x and places the company in the 91st percentile among healthcare peers, indicating it is one of the most highly valued stocks in its industry on a growth-adjusted basis. No trend data is available — the year-over-year, quarter-over-quarter, and historical values over the last eight quarters are all listed as N/A, with only the single current figure of 4.82x provided. Without a trend, the very high level alone suggests above-average valuation risk, as investors are paying a steep premium for future growth relative to the sector. This metric contradicts the overall NEUTRAL verdict, as a PEG ratio this far above the sector median typically signals a bearish outlook rather than a balanced risk-reward profile.

Frequently Asked Questions

Closest Sector Peers